# Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

> **NCT00428077** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** bcr-abl peptide vaccine
- **GENETIC:** reverse transcriptase-polymerase chain reaction

## Key facts

- **NCT ID:** NCT00428077
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-10
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Withdrawn because there were no dramatic changes in the main endpoint, as well as low enrollment numbers. The data are not interpretable in terms of efficacy.
- **Last updated:** 2011-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00428077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00428077, "Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00428077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*